ASML Holding vs Pfizer: Founders, CEOs and History
ASML Holding was founded in 1984 by Philips Electronics, Arthur del Prado and is led by Christophe Fouquet. Pfizer was founded in 1849 by Charles Pfizer, Charles Erhart and is led by Albert Bourla.
Company facts
ASML Holding
- Founded
- 1984
- Headquarters
- Veldhoven, Netherlands
- Current CEO
- Christophe Fouquet
- Employees
- 44,209
Pfizer
- Founded
- 1849
- Headquarters
- New York, New York
- Current CEO
- Albert Bourla
- Employees
- 75,000
Founders
ASML Holding
Philips Electronics
ASML was not founded by an individual with a vision. It was an underfunded joint venture between a conglomerate that wanted a project off its books and a smaller equipment company that wanted into lithography.
Arthur del Prado
Del Prado contribution to ASML was structural and financial rather than technical.
Pfizer
Charles Pfizer
Pfizer possesses a historic, immigrant founding story, rooted entirely in the rapid industrial expansion of 19th-century Brooklyn and defined by an effective, intensely meticulous German chemist and his ambitious confectioner cousin.
Charles Erhart
Charles Erhart's role in Pfizer's founding is less celebrated than his cousin's, partly because the company carries Charles Pfizer's name and partly because his commercial contributions were less visible than the scientific achievements that drove the company'…
CEOs and their tenures
ASML Holding
- Willem Maris1990–1999
President and Chief Executive Officer
Willem Maris was recruited from the Philips managerial ranks to run ASML in 1990, when the company was still loss-making and dependent on parent funding. His first task was keeping it solvent through the early 1990s downturn.
Source - Doug Dunn1999–2004
President, Chief Executive Officer and Chairman of the Board
Doug Dunn took over as president and chief executive on April 1, 1999 and ran ASML through the dot-com boom and the sharp semiconductor downturn that followed.
Source - Eric Meurice2004–2013
President and Chief Executive Officer
Eric Meurice was appointed president and chief executive effective October 1, 2004, joining from Thomson where he ran the television division.
Source - Peter Wennink2013–2024
President and Chief Executive Officer
Peter Wennink joined ASML as chief financial officer in 1999 after a career at Deloitte Accountants covering semiconductor clients, and became chief executive on July 1, 2013, leading the company jointly with technology chief Martin van den Brink.
Source - Christophe Fouquet2024–present
President, Chief Executive Officer and Chair of the Board of Management
Christophe Fouquet became president and chief executive on April 24, 2024, succeeding Peter Wennink and Martin van den Brink.
Source
Pfizer
- Ian Read2010–2018
Chief Executive Officer
He ruthlessly cut R&D spending and eliminated tens of thousands of jobs, significantly boosting short-term earnings per share despite massive patent cliffs for blockbuster drugs like Lipitor.
Source - Albert Bourla2019–present
Chairman and Chief Executive Officer
A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.
Source - Dave Denton2022–2026
Chief Financial Officer
As CFO, he aggressively restructured the balance sheet following the Seagen acquisition, prioritizing debt reduction while defending the dividend.
Source - Chris Boshoff2025–present
Chief Scientific Officer and President, Research & Development
He completely restructured the research and development organization to focus on antibody-drug conjugates (ADCs), aggressively expanding Pfizer's pipeline of cancer therapeutics.
Source - Cecile Guegan2026–present
Interim Chief Financial Officer
She modernized the company's internal auditing and compliance structures, ensuring rapid but safe clinical execution for high-priority vaccine programs.
Source
Timeline: ASML Holding and Pfizer side by side
1849Pfizer
Pfizer Founded
Charles Pfizer and Charles Erhart founded the company in Brooklyn.
1944Pfizer
Penicillin Scale-Up
Pfizer helped industrialize penicillin production during World War II.
1984ASML Holding
Founded as ASM Lithography in Eindhoven
ASM Lithography starts operations on April 1, 1984 as a joint venture between Philips and ASM International, with the mandate to commercialize the PAS 2000 wafer stepper developed inside Philips.
1986ASML Holding
PAS 2500 stepper and the Carl Zeiss partnership
ASML brings the PAS 2500 stepper to market with a new wafer alignment system developed by first chief scientist Steef Wittekoek, and establishes the optics partnership with Carl Zeiss that still supplies every ASML lithography system.
1988ASML Holding
ASM International withdraws and Philips funds a rescue
With few customers and heavy cash consumption, ASM International decides to stop funding the joint venture while Philips launches a company-wide cost-cutting program.
1991ASML Holding
PAS 5500 platform turns the company around
ASML launches the PAS 5500 platform, whose productivity and resolution win the first large orders from Intel and IBM under chief executive Willem Maris and take the company to profitability. PAS 5500 systems are still running in customer fabs decades later.
1995ASML Holding
IPO in Amsterdam and on Nasdaq
ASML becomes a fully independent public company with a dual listing on the Amsterdam Stock Exchange and Nasdaq. Philips sells half of its shares at the IPO and divests the remainder over the following years.
1998Pfizer
Viagra Approved
The FDA approved Viagra in 1998.
2000Pfizer
Warner-Lambert Deal
Pfizer acquired Warner-Lambert, adding Lipitor.
2001ASML Holding
TWINSCAN platform launched and Silicon Valley Group acquired
ASML introduces the TWINSCAN dual-stage architecture, which exposes one wafer while the next is measured and aligned, lifting throughput and overlay accuracy above competing systems.
2003ASML Holding
First immersion lithography system
The TWINSCAN AT:1150i debuts as ASML's first immersion machine, projecting 193 nanometer light through a layer of ultrapure water between the lens and the wafer to raise resolution.
2010ASML Holding
First EUV prototype shipped
ASML ships the TWINSCAN NXE:3100, its first extreme ultraviolet lithography tool, to the research facility of an Asian chipmaker.
2012ASML Holding
Customer Co-Investment Program with Intel, TSMC and Samsung
Intel, TSMC and Samsung acquire newly issued ASML shares equal to an aggregate 23 percent minority stake for ~$4.35 billion (3.85 billion euros) in cash, and separately commit ~$1.56 billion (1.38 billion euros) of R&D funding over five years dedicated to EUV…
2013ASML Holding
Cymer acquisition completed and second-generation EUV shipped
ASML completes the acquisition of Cymer, the San Diego supplier of the light sources used in its lithography systems, in a cash-and-stock deal valued at ~$2.2 billion (1.95 billion euros) when it was agreed in October 2012.
2017ASML Holding
EUV enters high-volume manufacturing
ASML begins shipping the production-ready TWINSCAN NXE:3400B after customers started ordering the NXE:3400 generation in batches in 2016, roughly two decades after EUV research began.
2019ASML Holding
Dutch government stops EUV exports to China
The Netherlands does not renew ASML's export licence for EUV systems to China, the start of a widening export control regime.
2019Pfizer
Albert Bourla becomes CEO
Albert Bourla became CEO of Pfizer in 2019. A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.
2020Pfizer
BioNTech COVID Vaccine Partnership
Pfizer and BioNTech brought Comirnaty through emergency authorization.
2023ASML Holding
First High-NA EUV system shipped
ASML ships the first of its next-generation EUV systems with a numerical aperture of 0.55, the TWINSCAN EXE:5000, to Intel in Hillsboro, Oregon.
2023Pfizer
Seagen Acquisition
Pfizer completed the $43 billion Seagen acquisition.
2024ASML Holding
Christophe Fouquet becomes chief executive
Peter Wennink and Martin van den Brink step down as presidents of ASML on April 24, 2024 and Christophe Fouquet becomes president, chief executive officer and chair of the Board of Management.
2025ASML Holding
Record year, first EXE:5200B and Mistral AI investment
ASML reports total net sales of ~$37 billion (32.7 billion euros), up 15.6 percent, net income of ~$10.8 billion (9.6 billion euros), a gross margin of 52.8 percent and 535 systems sold, and closes the year with a backlog of ~$43.8 billion (38.8 billion euros)…
2025Pfizer
Chris Boshoff Becomes CSO
Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
2025Pfizer
Metsera Acquisition
Pfizer completed its acquisition of obesity drug developer Metsera in November 2025 for up to about $10 billion including CVRs.
2025Pfizer
FY2025 Revenue Base
Pfizer reported $62.579 billion of FY2025 revenue.
2026Pfizer
Innovent Oncology Collaboration
Pfizer signed a 12-program cancer collaboration with Innovent Biologics: $650 million upfront and up to $9.85 billion in milestones.
Acquisitions
ASML Holding
- Berliner Glas Group2020Undisclosed
- Hermes Microvision Inc. (HMI)2016$3.1B
- Cymer Inc.2013$2.6B
- Brion Technologies2007$270M
- Silicon Valley Group (SVG)2001$1.6B
Pfizer
- Metsera, Inc.2025$7B
- Seagen Inc.2023$43B
- Medivation Inc.2016$14B
- Wyeth2009$68B
- Pharmacia Corporation2003$60B
- Warner-Lambert Company2000$111B
Questions about ASML Holding vs Pfizer
Who is the CEO of ASML Holding NV and Pfizer Inc.?
ASML Holding NV is led by Christophe Fouquet and Pfizer Inc. is led by Albert Bourla. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was ASML Holding NV founded vs Pfizer Inc.?
Pfizer Inc. was founded in 1849 — 135 years before ASML Holding NV, which was founded in 1984. Pfizer Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger ASML Holding NV.
How many employees does ASML Holding NV have compared to Pfizer Inc.?
ASML Holding NV employs approximately 44,209 people, while Pfizer Inc. employs approximately 75,000. Pfizer Inc. has the larger workforce at 75,000 employees, compared to ASML Holding NV's 44,209. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are ASML Holding NV and Pfizer Inc. headquartered?
ASML Holding NV is headquartered in Netherlands and Pfizer Inc. is headquartered in United States. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded ASML Holding NV and Pfizer Inc.?
ASML Holding NV was founded by Philips Electronics, Arthur del Prado. Pfizer Inc. was founded by Charles Pfizer, Charles Erhart.
Which company has a longer operating history — ASML Holding NV or Pfizer Inc.?
Pfizer Inc. has been operating for approximately 177 years, making it the more established of the two companies. ASML Holding NV has been in operation for around 42 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the ASML Holding vs Pfizer overview